A Trial of Bleomycin versus Adriamycin in Advanced Carcinoma of the Bladder
- 1 April 1979
- journal article
- Published by Wiley in British Journal of Urology
- Vol. 51 (2), 121-124
- https://doi.org/10.1111/j.1464-410x.1979.tb02844.x
Abstract
Thirty-seven patients were studied in a controlled clinical trial to assess the value of Adriamycin and Bleomycin in the treatment of advanced carcinoma of the bladder. The previously reported high response rates for both drugs were not observed in this trial. Administration of Bleomycin was accompanied by a toxicity rate so high that treatment had to be abandoned. Neither Adriamycin nor Bleomycin, therefore, used as single agents, have a role in the chemotherapy of advanced bladder cancer. Other agents should be investigated and assessed by controlled clinical trials that are disease-orientated rather than drug-orientated.Keywords
This publication has 12 references indexed in Scilit:
- The Treatment of Advanced Bladder Cancer with MethotrexateBritish Journal of Urology, 1977
- The Management of Deeply Infiltrating (T3) Bladder Carcinoma: Controlled Trial of Radical Radiotherapy versus Preoperative Radiotherapy and Radical Cystectomy (First Report)British Journal of Urology, 1976
- Single-Drug Chemotherapy of Bladder Cancer with Adriamycin, VM-26 or BleomycinEuropean Urology, 1976
- Chemotherapy of Bladder Carcinoma with Cyclophosphamide and AdriamycinJournal of Urology, 1975
- The chemotherapy of urologic cancerCancer, 1975
- Phase II evaluation of adriamycin in human neoplasiaCancer, 1973
- Adriamycin—an antitumor antibiotic in the treatment of neoplastic diseasesCancer, 1973
- Clinical Trials of AdriamycinPublished by Springer Nature ,1972
- Clinical Trials with Adriamycin. Results of Three-Years StudyPublished by Springer Nature ,1972
- Clinical trials with adriamycinCancer, 1971